Genmab — November 2024

[Bulder]

Nu er anitocaptagene ikke blandt dem du linker til. Dennes cr rate er flot, selv om den ikke er 100%. Mange vil kunne leve livet ud med MM efter cd38 og car-t.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[bibob]

God morgen.

[ProinvestorNEWS]

Genmab stiller med 20 indlæg ved ASH-konference https://proinvestor.com/investornyt/1238337/genmab-stiller-med-20-indlaeg-ved-ash-konference

[LP90]

Godmorgen

[E_L]

Genmab to Highlight Epcoritamabs Promising Role in Non-Hodgkin Lymphoma Treatment at ASH Annual Meeting https://csimarket.com/news/genmab-to-highlight-epcoritamab-s-promising-role-in-non-hodgkin-lymphoma-treatment-at-ash-annual-meeting2024-11-06026109

[E_L]

Minhua Chu
@chuminhua432
?? $ABBV AbbVie's BLA for epcoritamab (Epkinly) has been accepted by China's NMPA. https://x.com/chuminhua432/status/1854089849185460624

[E_L]

same in chinese https://www.forbeschina.com/innovation/innovation/69032

[lahn1]

Gentogen 17:29, er det data fra EPCORE DLBCL-1 ? kan ikke selv finde dem

[lahn1]

EPCORE DLBCL-2 må det være ?

[gentogen]

Ja: 581 Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

[gentogen]

Paper: Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

(ash.confex.com)

[Solsen]

Det er ret vilde responser og duration.

[Solsen]

Spændende at følge videre frem. Epco kan blive meget stort.

[lahn1]

Tak det ser rigtig fint ud, hvis vi kan holde AE's nede. Kæmpe markedet med 50/50 ejerskab

[Solsen]

Synes AEs ser rimelige ud. CRS er low grade. 2 stk G5 som næppe er epcos skyld.

[E_L]

small new (sub)trial - Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
https://clinicaltrials.gov/study/NCT06676033

[Raun]

Samme handelsmønster som i går.... - Spændende at se hvor langt aktien skal trykkes ned

[E_L]

https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches Genmab and AbbVie’s debut of Epkinly for patients with diffuse large B-cell lymphoma has also exceeded expectations in its battle with
Columvi.